|  Sign up!  

scientia

Return to Course Listing

 

 

CME: Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

 


Program Description / Statement of Need:

In this online CME self-learning program:

 

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.(1) While MM only makes up about 1% of all cancers, it the most common of the blood cancers, and its incidence has risen from the lower end of 22,000 cases per year five years age to an estimated 26,850 in 2015; mortality rates have stayed consistent at approximately 11,000 per year. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

 

Agenda:

 

Faculty introduction, disclosures

Introduction content [Learning Objective #1]

  • Statistics and prognosis: Overall survival
  • Pathophysiology: germinal center plasma cells, B cell precursor, clonal evolution theory, bone marrow microenvironment, dysregulation of the cyclin D / retinoblastoma pathway
  • Most recent IMWG diagnostic criteria, smoldering myeloma, revised ISS, cytogenetic abnormality highlights

Updates in treatment in patients with MM [Learning Objectives #2, 3, & 4]

  • Transplant eligibility, induction, regimens, and related clinical trial updates
  • Evaluation of treatment response
  • Relapsed myeloma
  • Present pharmacotherapy and update in clinical trial evidence
  • Investigational agents
  • Principles in supportive care
  • Clinical challenges including complication management
  • The role of the clinician as educator
  • Patient case(s)

Summary, conclusions, and best practice recap


 

Target Audience:

Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.



Program Objectives:

By the end of the session the participant will be able to:

    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.


    Accreditation:

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

     

    Credit Designation: ScientiaCME designates this educational activity for a maximum of  1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     

    Pharmacists

     

    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-17-042-H01-P.  ACPE Accreditation effective 11/2/17, expires 11/2/19. This is a Knowledge (K)-type activity.



    Release Date: November 02, 2017
    Expiration Date: November 02, 2019

    Faculty: Ravi Vij MD MBA


    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure:  Ravi Vij, MD, Professor of Medicine, Washington University School of Medicine, Section of Stem Cell Transplant and Leukemia, St. Louis, Missouri, has received grants from Amgen and Takeda, and serves as a consultant to Jazz, Abbvie, Karyopharma Amgen, Takeda, Celgene, BMS, and Janssen.

     

    Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.

     

    Commercial Support Disclosure: This program is supported by educational grants from AMGEN.


    Additional Courses That Are Related To This Course


    Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options

    Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

    Advancing Treatment Strategies in Acute Lymphoblastic Leukemia (ALL) Drug Therapy

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.


    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



This program is supported by educational grants from AMGEN.

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.